SBIR Phase II: Hybrid Inorganic/Organic Ion Exchange Material for the 227Ac/223Ra Generator

SBIR 第二阶段：用于 227Ac/223Ra 发生器的混合无机/有机离子交换材料

• 批准号: 0450581
• 负责人: Hariprasad Gali
• 金额: --
• 依托单位: Lynntech, Inc
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-04-15 至 2007-03-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0450581&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Hybrid; Inorganic

This Small Business Innovation Research (SBIR) Phase II project aims to develop a generator to produce pure radium-223 for use in cancer therapy. The alpha-emitter Ra-223 has a longer half-life than the other alpha-emitting radioisotopes (213 Bi, 212Bi and 211At) that are currently being evaluated for use in radio-immunotherapy (RIT), and has been shown to have higher bone uptake than the commercially available beta-active bone seekers. This makes it very attractive for Ra-223 to be developed further for radiopharmaceutical applications and for use as a pain palliation agent. However, the research and clinical application of this isotope are hindered by the limited availability of pure Ra-223. A simple technique to produce the isotope is a generator where a suitable parent, in this case Ac-227, is immobilized on an ion exchanger column and Ra-223 is eluted when required. Current separation methods frequently use organic resins, which tend to degrade under ionizing radiation and thus the product may contain impurities. Prior Phase I work developed new hybrid inorganic/organic ion exchange materials with high affinity for actinium, but low affinity for radium and good resistance against radiation. The Phase II project will optimize the exchanger performance and fabricate a prototype of the Ra-223 generator.The commercial application of this project will be in the area of cancer therapy. It is expected that the easy - to - use generator, which poses a smaller radiation hazard to personnel, will be used at medical research centers, radio - pharmacies and hospitals to produce pure radium - 223 to treat patients with bone metastases and other small solid tumors.

这个小型企业创新研究 (SBIR) 第二阶段项目旨在开发一种发生器来生产用于癌症治疗的纯镭 223。 α 发射体 Ra-223 比目前正在评估用于放射免疫治疗 (RIT) 的其他 α 发射放射性同位素（213 Bi、212Bi 和 211At）具有更长的半衰期，并且已被证明具有更高的半衰期。骨吸收率高于市售的 β 活性骨吸收剂。 这使得 Ra-223 进一步开发用于放射性药物应用和用作疼痛缓解剂非常有吸引力。 然而，该同位素的研究和临床应用因纯 Ra-223 的供应有限而受到阻碍。 生产同位素的一种简单技术是使用发生器，将合适的母体（在本例中为 Ac-227）固定在离子交换柱上，并在需要时洗脱 Ra-223。 目前的分离方法经常使用有机树脂，其在电离辐射下容易降解，因此产品可能含有杂质。 前期第一阶段工作开发了新型混合无机/有机离子交换材料，对锕具有高亲和力，但对镭具有低亲和力，并且具有良好的抗辐射性。二期项目将优化交换器性能并制造Ra-223发生器原型。该项目的商业应用将在癌症治疗领域。 预计这种对人员辐射危害较小、使用方便的发生器将在医学研究中心、放射性药房和医院中使用，生产纯镭223，用于治疗骨转移瘤和其他细小固体的患者。肿瘤。